Form 4: Athira Pharma Director James A. Johnson Granted 20,900 Stock Options
Insider Transaction Report (Form 4)
Athira Pharma, Inc. Director James A. Johnson was granted 20,900 stock options with an exercise price of $0.3125 as part of the company's outside director compensation policy.
Summary
- James A. Johnson, a Director of Athira Pharma, Inc. (ATHA), was granted 20,900 stock options on May 30, 2025.
- The stock options have an exercise price of $0.3125 per share.
- The options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
- The expiration date for these stock options is May 29, 2035.
- This grant was made pursuant to the terms of Athira Pharma, Inc.'s Outside Director Compensation Policy.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event that aligns director interests with shareholders, which is generally viewed favorably, but it does not indicate any significant new operational or financial developments.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
- This is a routine compensation action, indicating adherence to established corporate governance policies for outside directors.
Future Outlook
The granted stock options are subject to a future vesting schedule, occurring on the earlier of May 30, 2026, or the day before the next annual meeting of stockholders after May 30, 2025, and will expire on May 29, 2035.
Management Comments
- The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Industry Context
This Form 4 filing is a standard disclosure for insider transactions, specifically the grant of equity compensation to a director. Such grants are common practice across publicly traded companies to attract and retain qualified board members and align their interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Application | The grant of stock options to Director James A. Johnson was made under the Issuer's existing Outside Director Compensation Policy, demonstrating the ongoing application of established corporate governance frameworks for executive and director remuneration. | 05/30/2025 | Reinforces adherence to a structured compensation policy, promoting transparency and alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders: The grant of stock options to a director helps align their long-term interests with those of the shareholders, potentially leading to better governance and strategic decisions aimed at increasing shareholder value.
Next Steps
- Vesting of the 20,900 stock options based on the specified conditions (May 30, 2026, or the day before the next annual meeting after May 30, 2025).
Key Dates
| Date | Description |
|---|---|
| 05/30/2025 | Date of earliest transaction; grant date of the stock option. |
| 06/03/2025 | Date the Form 4 was filed. |
| 05/30/2026 | Earliest potential vesting date for the stock option. |
| 05/29/2035 | Expiration date of the stock option. |
Keywords
Athira Pharma, ATHA, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.